(Reuters) – Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the treatment of adults with moderate to severe hemophilia B. The company said the discontinuation was due to several reasons, including limited interest in gene therapies for the bleeding